Delivered to your Trust or directly to your Patient:
Kinpeygo® – the first and only disease-modifying treatment approved across Europe and by NICE specifically for use in IgA nephropathy1,2
Kinpeygo® is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with urine protein-to-creatinine ratio (UPCR) ≥ 1.5g/gram
Prescribing Information can be found here
Request a visit from our Medical Science Liaison Team or Healthcare Partnership Manager Team
Order via HealthNet Homecare for delivery to your Trust or direct to your patient.
Want to be the first to hear about the products, services and educational resources we offer, including invitations to webinars and events?
1. European public assessment report (EPAR) Kinpeygo. EMA/570757/2022, last revised 05/2022. 2. Overview | Targeted-release budesonide for treating primary IgA nephropathy | Guidance | NICE. https://www.nice.org.uk/guidance/ta937 (Published: 20 December 2023).
For information on our products please visit EMC, https://www.medicines.org.uk/emc/ and search the product for a Summary of Product Characteristics
Adverse events should be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164. Additionally, reporting forms and information can be found at: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.
UK-MULT-122e(2) | Date of Preparation: May 2024
I am a UK Healthcare Professional
The information on our Healthcare Professional Website is solely intended for UK Healthcare Professionals and contains promotional information. Click here to return to our main public site.
For information on our products please visit EMC and search the product for a Summary of Product Characteristics.